Clinical Trial Detail

NCT ID NCT03308942
Title Effects of Single Agent Niraparib and Niraparib Plus Programmed Cell Death-1 (PD-1) Inhibitors in Non-Small Cell Lung Cancer Participants
Recruitment Active, not recruiting
Gender both
Phase Phase II
Variant Requirements Yes
Sponsors Tesaro, Inc.
Indications

lung non-small cell carcinoma

Therapies

Niraparib

Niraparib + Pembrolizumab

Dostarlimab + Niraparib

Age Groups: adult senior

Additional content available in CKB BOOST